Product Description
OnabotulinumtoxinA (Botox®; a formulation of botulinum toxin type A (BoNT/A)] is indicated for the prevention of headaches in adults with chronic migraine (CM) in numerous countries, including those of Europe. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33314008/)
Mechanisms of Action: SNAP-25 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Israel, Italy, Japan, Korea, Netherlands, Norway, Poland, Russia, Slovakia, Spain, Sweden, Switzerland, Taiwan, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 72
Highest Development Phases
Phase 3: Atrial Fibrillation|Cerebral Palsy|Chronic Pain|Dyspareunia|Glabellar Reflex|Hyperhidrosis|Migraine Disorders|Multiple Sclerosis|Muscle Spasticity|Other|Overactive Bladder|Pelvic Pain|Sialorrhea|Spinal Cord Injuries|Stroke|Traumatic Brain Injury
Phase 2: Chronic Obstructive Pulmonary Disease|Cystitis, Interstitial|Enuresis|Essential Tremor|Neuralgia|Neuralgia, Postherpetic|Neuropathic Pain|Pancreatic Fistula|Paraplegia|Paresis|Peripheral Nerve Injuries|Trigeminal Neuralgia|Urinary Incontinence, Urge
Phase 1: Healthy Volunteers|Urinary Incontinence, Stress
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-000240-22 | P3 |
Active, not recruiting |
Unknown |
2034-05-24 |
|
| 2017-000642-22 | P3 |
Active, not recruiting |
Chronic Pain|Pelvic Pain |
2029-07-12 |
|
| jRCT2061240117 | P3 |
Recruiting |
Unknown |
2026-11-30 |
|
| RELIEF | P2 |
Recruiting |
Overactive Bladder|Urinary Incontinence, Urge|Enuresis |
2026-09-01 |